Fully human agonist antibodies to TrkB using autocrine cell-based selection from a combinatorial antibody library.

ABSTRACT: The diverse physiological roles of the neurotrophin family have long prompted exploration of their potential as therapeutic agents for nerve injury and neurodegenerative diseases. To date, clinical trials of one family member, brain-derived neurotrophic factor (BDNF), have disappointingly failed to meet desired endpoints. Contributing to these failures is the fact that BDNF is pharmaceutically a nonideal biologic drug candidate. It is a highly charged, yet is a net hydrophobic molecule with a low molecular weight that confers a short t_1/2 in man. To circumvent these shortcomings of BDNF as a drug candidate, we have employed a function-based cellular screening assay to select activating antibodies of the BDNF receptor TrkB from a combinatorial human short-chain variable fr

SUBMITTER: Merkouris S 

PROVIDER: S-EPMC6065019 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature